To all relevant enterprises:
InDriven by the “14th Five-Year Plan” for Cold Chain Logistics Development and cold chain policies in various regions, in the past two years,Pharmaceutical Cold ChainMaintain a strong momentum of rapid development.Data shows that,2022In [year], the market size of China's pharmaceutical cold chain logistics reached1621.12100 million yuan.The "2022“Annual Statistical Analysis Report on the Operation of the Pharmaceutical Distribution Industry” shows that the proportion of cool storage warehouses has increased from2021Annual59.8%Increase to71.9%；Cold storage volume from93.910,000 cubic meters, surging to14910,000 cubic meters.As domestic R&D investment in innovative drugs continues to increase, the market size of biologics grows rapidly, and relevant regulatory policies are gradually implemented, commercial biological product cold chain services account for the largest share in the biomedical cold chain service segment. The market size reached RMB 16.7 billion in 2022, while the fields of cold chain services for innovative drug R&D and medical device distribution cold chain services have shown strong growth rates, with market sizes reaching RMB 3.2 billion and RMB 4.8 billion respectively in 2022. It can be foreseen that with the expansion of biomedical R&D, IVD (In Vitro Diagnostics), as well as vaccines,Blood ProductsWith the increasing demand, the pharmaceutical cold chain industry will enter a golden period of development.
Act at the Right Time, Emerge with the Trend. Against the backdrop of major trends in pharmaceutical logistics—namely digitalization, standardization, and green development—the commercialization of innovative drugs is accelerating. The coordination among multiple warehouses and the construction of shared cold-chain logistics platforms are continuously advancing, while regulations and supervisory policies concerning pharmaceutical logistics, such as drug traceability, are becoming increasingly stringent. Consequently, there is a growing demand among enterprises for win-win cooperation and collaborative development. In light of this, supported by the Pharmaceutical Commerce Professional Committee of the China General Chamber of Medicine Industry under the All-China Federation of Industry and Commerce, and organized by the YaoLianQuan Platform, the “2024 (10th) International Summit on the Full Industrial Chain of Pharmaceutical Cold Chain” will be held. The event will invite leaders from relevant national departments and renowned industry experts to engage in in-depth discussions on hot topics of concern to the sector, including policies, technologies, innovative development, and lean management related to the pharmaceutical cold-chain industrial chain. Meanwhile, the summit aims to build a platform for exploring practical models of enterprise cooperation.1. Organizational Structure
Supporting Organizations:Pharmaceutical Commerce Special Committee of the China General Chamber of Commerce-Pharmaceutical Industry ChamberOrganizer: PharmaChain Circle Platform
Co-organizer: Pharmaceutical Commerce Branch of China Medical Pharmaceutical Material Association
Taizhou Pharmaceutical Association
Tianjin Yaolian Zhiqi Supply Chain Technology Co., Ltd.
Organizer:Beijing Yingshidai Supply Chain Management Co., Ltd.Digital Intelligence Empowerment: Meeting Challenges Head-OnLocation: Taizhou, Jiangsu400 people
1. Practical Training on Comprehensive Risk Control for Pharmaceutical Cold Chain2.Biopharmaceutical Cold Chain Service Innovation Forum
3.Forum on Cold Chain Safety Management for Pharmaceuticals
4.Pharmaceutical Logistics and Technical Equipment Exhibition
5.Annual Awards for the Pharmaceutical Cold Chain Series
6. ProposedVisit to the Logistics Center of Yangtze River Pharmaceutical Group Commercial Company1. Trend Analysis and Future Prospects of China's Pharmaceutical Cold Chain Industry2. Challenges and Transformation of Pharmaceutical Cold Chain in a Volatile Economic Landscape3. Discussion on Cold Chain Logistics Service Models for Innovative Drug R&D4. Discussion on Business Model Innovation in IVD Enterprises5. The Importance of Quality and Risk Management in Pharmaceutical Cold Chain Management6. The Promotion and Practical Application of New Technologies/New Materials in the Development of Pharmaceutical Cold Chain7. Lean Management of Pharmaceutical Cold Chain Logistics8. How to Establish a Feasible Drug Traceability System9. Digital Intelligence Empowerment: Exploration and Application in Pharmaceutical Cold Chain10.Cold Chain PharmaceuticalsEmergency Plan for Storage and Transportation
Most Beautiful Quality Professional in Pharmaceutical Cold Chain Logistics (2023-2024)
2023-2024 Elite Figures in Pharmaceutical Cold Chain LogisticsRecommended Enterprises for Pharmaceutical Cold Chain Logistics Services (2023-2024)Recommended Enterprises for Pharmaceutical Cold Chain Technology and Equipment (2023–2024)Best Pharmaceutical Cold Chain Logistics Center (Base) of 2023-20248. Conference Composition
1.Representatives from government authorities, industry associations and chambers of commerce, research institutions, and academic experts;
2.Pharmaceuticals, medical device manufacturing, biological products, vaccines,IVD, blood products, insulin, startups, genetic testing, life sciences and commercial distribution enterprises, Centers for Disease Control and Prevention (CDCs), biopharmaceutical industrial parks, pharmaceutical logistics, cold chain technology and equipment, real estate, and other enterprises;3.Media outlets related to the pharmaceutical and healthcare sector, including websites, newspapers, and magazines.1. Training fee: RMB 1,500 per person, inclusive of training, materials, lunch, tea breaks, and venue costs;2. The registration fee is RMB 3,200 per person, covering conference fees, expert honoraria, materials, meals, and venue costs; transportation and accommodation expenses are to be borne by attendees.
3. The combined cost for the two activities—training and conference—is RMB 4,200 per person, covering expenses related to the training and conference activities; transportation and accommodation costs shall be borne by participants themselves.
4.Pharmaceuticals, medical device manufacturing, biological products, vaccines,IVD, blood products, insulin, and innovative drug companiesFree slots are subject to approval; additional fees apply for training participation.Contacts: Yang Bin, Yu Jing
Contact Number: 010-60315260 13269388636
